Your browser is no longer supported. Please, upgrade your browser.
Settings
RDY Dr. Reddy's Laboratories Limited daily Stock Chart
RDY [NYSE]
Dr. Reddy's Laboratories Limited
Index- P/E26.18 EPS (ttm)1.56 Insider Own27.70% Shs Outstand168.12M Perf Week1.34%
Market Cap6.85B Forward P/E23.20 EPS next Y1.76 Insider Trans0.00% Shs Float149.41M Perf Month0.67%
Income258.80M PEG2.06 EPS next Q- Inst Own13.60% Short Float0.91% Perf Quarter9.30%
Sales2.16B P/S3.17 EPS this Y-7.30% Inst Trans1.10% Short Ratio6.34 Perf Half Y15.76%
Book/sh11.86 P/B3.44 EPS next Y34.22% ROA7.60% Target Price28.03 Perf Year25.52%
Cash/sh2.14 P/C19.08 EPS next 5Y12.70% ROE13.30% 52W Range28.13 - 41.28 Perf YTD8.14%
Dividend0.29 P/FCF22.44 EPS past 5Y-7.40% ROI4.90% 52W High-1.24% Beta0.10
Dividend %0.71% Quick Ratio1.30 Sales past 5Y4.10% Gross Margin54.50% 52W Low44.93% ATR0.73
Employees23524 Current Ratio1.80 Sales Q/Q1.20% Oper. Margin12.20% RSI (14)60.92 Volatility1.79% 1.73%
OptionableYes Debt/Eq0.32 EPS Q/Q13.50% Profit Margin11.70% Rel Volume0.52 Prev Close40.24
ShortableYes LT Debt/Eq0.18 EarningsMay 03 BMO Payout- Avg Volume215.63K Price40.77
Recom- SMA201.44% SMA505.02% SMA20013.86% Volume111,164 Change1.32%
Feb-19-19Upgrade CLSA Outperform → Buy
Jan-17-19Downgrade Citigroup Neutral → Sell
Sep-21-17Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-31-17Upgrade CLSA Underperform → Outperform
Jul-28-17Downgrade CLSA Underperform → Sell
Jul-27-16Downgrade Jefferies Hold → Underperform
Jul-27-16Downgrade HSBC Securities Hold → Reduce
Feb-10-16Upgrade Credit Agricole Underperform → Buy
Nov-10-15Downgrade Citigroup Buy → Neutral
Jan-21-11Initiated HSBC Securities Overweight
Jan-19-10Downgrade Deutsche Bank Hold → Sell
Oct-26-09Upgrade Credit Suisse Neutral → Outperform
Jun-10-09Upgrade Citigroup Hold → Buy
Mar-07-08Downgrade Citigroup Buy → Hold
Jun-13-07Upgrade Credit Suisse Neutral → Outperform
May-21-07Upgrade JP Morgan Underweight → Neutral
Apr-17-19 12:05PM  Dr. Reddy's to Release Q4 and Full Year FY 19 Results on May 17, 2019 Business Wire
Apr-15-19 12:08PM  Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs Zacks
Apr-13-19 12:34PM  Dr. Reddy's Laboratories Announces Acquisition of ANDA Portfolio Business Wire
Apr-03-19 08:19AM  The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings Benzinga
Apr-02-19 08:15AM  Is India's 7.3% Growth Worth An Investment? Benzinga
01:54AM  Promius Pharma, LLC. (a Wholly Owned Subsidiary of Dr. Reddys Laboratories Ltd.) Announces the Sale and Assignment of the US Rights for Its Marketed Dermatology Brands to Encore Dermatology Business Wire
Apr-01-19 04:46PM  Supernus' ADHD Candidate Positive in 4th Phase III Study Zacks
Mar-28-19 08:32AM  Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL) Zacks
Mar-27-19 04:05AM  Dr. Reddy's Laboratories launches Tadalafil Tablets USP in the U.S. Market Business Wire
Mar-20-19 10:38AM  Top Ranked Momentum Stocks to Buy for March 20th Zacks
Mar-01-19 07:20AM  Factors of Influence in 2019, Key Indicators and Opportunity within Vanda Pharmaceuticals, Range Resources, Fortune Brands Home & Security, Dr. Reddy's Laboratories, BWX Technologies, and K12 New Research Emphasizes Economic Growth GlobeNewswire
Feb-27-19 06:16PM  Watching for Signs of Global Risk Events Investopedia
Feb-20-19 12:01PM  Dr. Reddy's Laboratories Announces the Re-Launch of Its Buprenorphine and Naloxone Sublingual Film after Favorable Ruling in Patent Litigation Business Wire
Feb-12-19 03:00AM  Dr. Reddy's Laboratories launches Tadalafil Tablets USP in the U.S. Market Business Wire
Feb-04-19 03:41PM  Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q3 Zacks
12:51AM  Dr. Reddy's Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling Business Wire
Feb-01-19 10:17AM  Dr. Reddy's Announces the Appointment of Marc Kikuchi to Lead Its Generics Business in North America Business Wire
09:27AM  Dr. Reddy's (RDY) Earnings Rise in Q3, Sales Increase Y/Y Zacks
07:45AM  Dr. Reddys Q3 FY19 Financial Results Business Wire
04:59AM  Dr. Reddy's third-quarter profit surges on strong growth in emerging markets Reuters
Jan-28-19 05:55PM  Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store? Zacks
Jan-27-19 11:53PM  Dr. Reddy's Laboratories and Its U.S. Subsidiary, Promius Pharma, Announce FDA Approval for TOSYMRA (Sumatriptan Nasal Spray) 10 mg, in the U.S. Market Business Wire
Jan-24-19 03:25AM  Dr. Reddy's Laboratories Announces the Launch of Propofol Injectable Emulsion, USP in the U.S. Market Business Wire
Jan-11-19 04:57AM  Dr. Reddy's to Release Q3 FY19 Results on February 1, 2019 Business Wire
Jan-10-19 02:54PM  Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility Zacks
10:05AM  Top-Ranked Sector ETFs & Stocks to Buy for 2019 Zacks
Jan-07-19 08:17AM  Dr. Reddy's Laboratories Limited to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-03-19 03:29PM  VIVUS (VVUS) Banks on New Drug Pancreaze, Qsymia Lacks Luster Zacks
03:03PM  Teva (TEVA) Ends Dispute with Amgen Over Generic Sensipar Zacks
Dec-31-18 08:04AM  The Zacks Analyst Blog Highlights: Internet Initiative Japan, Sony, Ingersoll-Rand, HDFC Bank and Dr. Reddy's Laboratories Zacks
Dec-28-18 09:55AM  Generic Industry on Path to Recovery: 3 Hot Picks for 2019 Zacks
09:05AM  5 ADRs That More Than Doubled the S&P 500 in 2018 Zacks
Dec-27-18 07:22AM  Highlighted as Zacks Bull and Bear of the Day Dr. Reddy???s Laboratories, Dillard???s, Facebook, Netflix and Amazon Zacks
02:03AM  Dr. Reddy's Laboratories Announces the Launch of Sevelamer Carbonate for Oral Suspension in the U.S. Market Business Wire
Dec-24-18 01:30AM  Dr. Reddy's Laboratories Launches Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market Business Wire
Dec-19-18 07:05AM  Today's Research Reports on Trending Tickers: Dr. Reddy's Laboratories and AbbVie ACCESSWIRE
Dec-18-18 10:30AM  Zacks.com featured highlights include: Abercrombie, Dr. Reddy???s, Cree, Otter and Shenandoah Zacks
Dec-14-18 08:11AM  Bet on These 5 Low-Beta Stocks to Fight Market Volatility Zacks
Dec-13-18 11:14AM  Should Warren Buffett And You Buy More TEVA Stock Right Now? InvestorPlace
Dec-11-18 09:23AM  Generic Drugmakers Down on Allegations of Price Fixing Zacks
06:57AM  Generic-drug stocks slammed by report of expanded price-fixing probe MarketWatch
12:43AM  Dr. Reddys announces the launch of over-the-counter store brand equivalent of Prilosec OTC® (Omeprazole Delayed-Release) Tablets, 20 mg in the U.S. Market Business Wire
Dec-10-18 11:30AM  Generic drug makers stocks fall sharply after report of expanded price-fixing probe MarketWatch
07:55AM  Factors of Influence in 2018, Key Indicators and Opportunity within OSI, BorgWarner, Cubic, Dr. Reddy's Laboratories, Teck Resources, and Gardner Denver New Research Emphasizes Economic Growth GlobeNewswire
Dec-07-18 09:01AM  These 5 stocks are surprising winners amid the markets wild swings MarketWatch
Dec-04-18 09:03AM  The Zacks Analyst Blog Highlights: Anthem, HCA, Dr. Reddy's and UnitedHealth Zacks
Dec-03-18 09:35AM  Healthcare Takes Wall Street Lead: 4 Picks Zacks
Nov-30-18 09:20AM  Zacks.com highlights: Marcus, Papa Murphy's Holdings, Dr. Reddy's Laboratories, Tesla and Spirit Airlines Zacks
09:15AM  Lilly (LLY) Hits Fresh High: Is There Still Room to Run? Zacks
Nov-29-18 09:41AM  5 Low-Beta Stocks to Weather Market Volatility Zacks
Nov-28-18 03:20AM  Dr. Reddy's Laboratories Announces the Launch of Chlorthalidone Tablets, USP in the U.S. Market Business Wire
Nov-21-18 12:15AM  Dr. Reddy's shares spike after favourable generic drug ruling Reuters
Nov-20-18 08:40PM  Dr. Reddy's Laboratories Announces Favorable Outcome in Buprenorphine and Naloxone Sublingual Film Patent Litigation Business Wire
Nov-19-18 08:57AM  J&J Gets Positive CHMP Opinion for Prostate Cancer Treatment Zacks
Nov-01-18 08:20AM  Consolidated Research: 2018 Summary Expectations for Dr. Reddy's Laboratories, Union Pacific, Zimmer Biomet, Varian Medical, Sonic Automotive, and Axalta Coating Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-31-18 03:51AM  Dr. Reddy's Laboratories Announces the Launch of Atomoxetine Capsules, USP in the U.S. Market Business Wire +5.16%
Oct-29-18 01:44PM  Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2 Zacks
Oct-26-18 09:29AM  Doctor Reddy's: Fiscal 2Q Earnings Snapshot Associated Press
09:22AM  Dr. Reddys Q2 & H1 FY19 Financial Results Business Wire
Oct-16-18 08:00AM  Today's Research Reports on Trending Tickers: Flex Pharma and Dr. Reddy's Laboratories ACCESSWIRE
Oct-15-18 06:12AM  Dr. Reddy's Laboratories Receives Approval for Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market Business Wire
12:48AM  Dr. Reddy's Laboratories Announces the Sale of Its API Manufacturing Business Unit in Jeedimetla, Hyderabad Business Wire
Oct-09-18 09:42AM  IMF Predicts Strong GDP Growth for India: Stocks in Focus Zacks
09:04AM  Dr. Reddy's Laboratories announces the launch of Colesevelam Hydrochloride Tablets in the U.S. Market Business Wire
Oct-03-18 09:42AM  Dr. Reddy's to Release Q2 FY19 Results on October 26, 2018 Business Wire
Oct-02-18 10:16AM  Dr. Reddy's Sells Antibiotic Production Hub to UAE Drugmaker Zacks
04:59AM  Dr. Reddy's Laboratories Announces the Sale of Cloderm® (clocortolone pivalate) Cream, 0.1% Franchise to EPI Health, LLC Business Wire
Oct-01-18 01:45AM  Dr. Reddy's Laboratories Announces the Launch of Imatinib Mesylate Tablets, USP in the U.S. Market Business Wire
01:44AM  Dr. Reddys Laboratories Announces That It Has Regained Worldwide Rights to DFA-02 Business Wire
01:36AM  Dr. Reddy's Laboratories Announces the Sale of Its Antibiotic Manufacturing Site and Its Related Assets in Bristol, Tennessee Business Wire
Sep-19-18 09:32AM  Dr. Reddy's (RDY) Presence in Generics Market Remains Strong Zacks
Sep-12-18 08:31AM  Dr. Reddy's Laboratories Announces the Launch of Neostigmine Methylsulfate Injection, USP in the U.S. Market Business Wire
Aug-10-18 09:11AM  The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Infosys, ICICI Bank and HDFC Bank Zacks
Aug-08-18 09:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddys Laboratories Ltd. - RDY ACCESSWIRE
Jul-30-18 07:10AM  Initiating Free Research Reports on Synergy Pharma and Three Other Drug Makers Equities ACCESSWIRE
Jul-27-18 09:34AM  Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q1 Zacks
Jul-26-18 04:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddys Laboratories Ltd. - RDY ACCESSWIRE
09:42AM  Doctor Reddy's: Fiscal 1Q Earnings Snapshot Associated Press
08:56AM  Dr. Reddys Q1 FY19 Financial Results Business Wire
06:24AM  Dr.Reddy's profit soars on anti-opioid drug sales in U.S. Reuters
05:40AM  India's Dr. Reddy's Q1 net profit rises seven-fold, beats forecast Reuters
12:46AM  Dr. Reddy's Laboratories Announces the Launch of Hervycta® (trastuzumab biosimilar) in India Business Wire
Jul-23-18 03:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddys Laboratories Ltd. RDY ACCESSWIRE
Jul-20-18 02:13AM  Dr. Reddys Announces the Launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg in the U.S. Market Business Wire
Jul-19-18 07:13PM  Indivior Finance S.ar.l. -- Moody's confirms Indivior's B3 Corporate Family Rating; revises outlook to negative Moody's
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Dr. Reddy's Laboratories Limited (RDY) PR Newswire
Jul-18-18 05:13PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddys Laboratories Ltd. RDY GlobeNewswire
Jul-17-18 08:00AM  Today's Research Reports on Stocks to Watch: Dr. Reddy's Laboratories and Intellia Therapeutics ACCESSWIRE
Jul-16-18 03:15PM  Dr.Reddys Laboratories (RDY) Dives Following Court Order InvestorPlace -10.41%
10:58AM  Indivior Soars on Court Ruling Blocking Sales of Rival's Generic Opioid Drug TheStreet.com
Jul-14-18 04:42AM  Dr. Reddy's Laboratories announces its intent to appeal court decision in preliminary injunction hearing for Buprenorphine and Naloxone Sublingual Film Business Wire
Jul-11-18 02:51AM  Dr. Reddy's Laboratories Announces the Launch of Hydroxychloroquine Sulfate Tablets, USP in the U.S. Market Business Wire
Jul-05-18 09:38AM  Dr. Reddy's to Release Q1 FY19 Results on July 26, 2018 Business Wire
Jun-28-18 07:35AM  Initiating Free Research Reports on Canopy Growth and Three Other Drug Makers Equities ACCESSWIRE
Jun-25-18 11:23AM  Lilly Wins Favorable Ruling From U.S. Court in Alimta Row Zacks
Jun-21-18 09:25PM  Spotlight On Dr Reddys Laboratories Limiteds (NSE:DRREDDY) Fundamentals Simply Wall St.
Jun-19-18 03:31AM  Dr. Reddy's Laboratories Announces the Launch of Levetiracetam in Sodium Chloride Injection in the U.S. Market Business Wire
Jun-18-18 10:09AM  Company News For Jun 18, 2018 Zacks
Jun-16-18 02:13AM  Dr. Reddy's Laboratories defends its right to launch Buprenorphine and Naloxone Sublingual Film in the U.S. Market Business Wire
01:59AM  Dr. Reddys Laboratories Limited announces filing of Annual Report on Form 20-F Business Wire
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. It also provides a portfolio of in-licensed dermatology products. As of March 31, 2018, this segment had 13 active products development programs pipeline that are in various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, pain management, oncology, dermatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.